Tumor Genetic Tests Point Rare Cancer Patients Toward Off-Label Drugs That Insurers Often Refuse to Cover

Tumor genetics can point to a drug approved for another cancer, but insurers often refuse to pay. What rare cancer patients can do.

Have A Referral?